中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

6 records (took 0.015 seconds)

    VACCINE
    1.
    发明申请
    VACCINE 有权
    疫苗

    公开(公告)号：US20140302094A1

    公开(公告)日：2014-10-09

    申请号：US14354117

    申请日：2012-10-24

    Applicant: university of Exeter

    Inventor： Richard W. Titball ,  Sérgio Paulo Fernandes Da Costa ,  Claire Naylor ,  Ajit Basak

    IPC: C07K14/33

    CPC classification number: C07K14/33 ,  A61K38/00 ,  A61K38/4893 ,  A61K39/00 ,  A61K39/08 ,  A61K2039/552 ,  C07K7/06 ,  C07K14/47

    Abstract: There is provided a NetB epitope polypeptide comprising at least 10 contiguous amino acids from SEQ ID NO:1 and comprising a mutation in at least one position between amino acids 130 and 297 as compared with the equivalent position in SEQ ID the mutation preferably being located within a rim domain, the polypeptide being capable of binding an antibody which binds to SEQ ID NO:1 and having reduced toxicity compared with the toxicity of SEQ ID NO:1. The polypeptide is useful to vaccinate a subject against infection by Clostridium perfringens.

    Abstract translation: 提供了包含SEQ ID NO：1的至少10个连续氨基酸的NetB表位多肽，并且在SEQ ID NO：1中与SEQ ID中的等同位置相比，其突变位于氨基酸130和297之间的至少一个位置，优选位于 边缘结构域，所述多肽能够结合与SEQ ID NO：1结合的抗体，并且与SEQ ID NO：1的毒性相比具有降低的毒性。 该多肽可用于使受试者免疫产气荚膜梭菌感染。

    Vaccine
    2.
    发明授权
    Vaccine 有权

    公开(公告)号：US10174086B2

    公开(公告)日：2019-01-08

    申请号：US15243409

    申请日：2016-08-22

    Applicant: University of Exeter

    Inventor： Richard W. Titball ,  Sergio Paulo Fernandes Da Costa ,  Claire Naylor ,  Ajit Basak

    IPC: C07H21/02 ,  C07H21/04 ,  C07K14/33 ,  A61K39/08 ,  A61K39/00

    Abstract: There is provided a NetB epitope polypeptide comprising at least 10 contiguous amino acids from SEQ ID NO:1 and comprising a mutation in at least one position between amino acids 130 and 297 as compared with the equivalent position in SEQ ID NO:3, the mutation preferably being located within a rim domain, the polypeptide being capable of binding an antibody which binds to SEQ ID NO:1 and having reduced toxicity compared with the toxicity of SEQ ID NO:1. The polypeptide is useful to vaccinate a subject against infection by Clostridium perfringens.

    EPSILON TOXIN EPITOPES FROM CLOSTRIDIUM PERFRINGENS WITH REDUCED TOXICITY
    3.
    发明申请
    EPSILON TOXIN EPITOPES FROM CLOSTRIDIUM PERFRINGENS WITH REDUCED TOXICITY 有权
    EPSILON毒素来自于具有降低毒性的隐孢子虫

    公开(公告)号：US20150064207A1

    公开(公告)日：2015-03-05

    申请号：US14387809

    申请日：2013-03-28

    Applicant: UNIVERSITY OF EXETER

    Inventor： Richard W. Titball ,  Monika Bokori-Brown ,  Claire Naylor

    IPC: C07K14/33 ,  C07K16/12

    CPC classification number: C07K14/33 ,  A61K39/00 ,  A61K39/08 ,  C07K16/1282

    Abstract: There is provided an epsilon toxin epitope polypeptide comprising a sequence of at least 10 contiguous amino acids from SEQ ID NO:3, the sequence comprising a mutation of at least one tyrosine residue compared to the equivalent sequence in SEQ ID NO:3, the polypeptide being capable of binding an antibody which binds to SEQ ID NO:5 and having reduced toxicity compared with the toxicity of SEQ ID NO:5. The polypeptide is useful in a method of vaccinating a subject against developing a disease caused by Clostridium perfringens and/or caused by (or associated with the presence of) active epsilon toxin.

    Abstract translation: 提供了包含SEQ ID NO：3的至少10个连续氨基酸的序列的ε-毒素表位多肽，所述序列包含与SEQ ID NO：3中的等同序列相比至少一个酪氨酸残基的突变，所述多肽 能够结合与SEQ ID NO：5结合的抗体，并且与SEQ ID NO：5的毒性相比具有降低的毒性。 该多肽可用于接种受试者以发展由产气荚膜梭菌引起的疾病和/或由活动性ε毒素（或与其存在）引起的疾病的疫苗接种的方法。

    VACCINE
    4.
    发明申请
    VACCINE 审中-公开
    疫苗

    公开(公告)号：US20170051023A1

    公开(公告)日：2017-02-23

    申请号：US15243409

    申请日：2016-08-22

    Applicant: University of Exeter

    Inventor： Richard W. Titball ,  Sergio Paulo Fernandes Da Costa ,  Claire Naylor ,  Ajit Basak

    IPC: C07K14/33 ,  C12N7/00

    CPC classification number: C07K14/33 ,  A61K39/08 ,  A61K2039/552 ,  A61K2039/575 ,  A61K2039/6006

    Abstract: There is provided a NetB epitope polypeptide comprising at least 10 contiguous amino acids from SEQ ID NO:1 and comprising a mutation in at least one position between amino acids 130 and 297 as compared with the equivalent position in SEQ ID NO:3, the mutation preferably being located within a rim domain, the polypeptide being capable of binding an antibody which binds to SEQ ID NO:1 and having reduced toxicity compared with the toxicity of SEQ ID NO:1. The polypeptide is useful to vaccinate a subject against infection by Clostridium perfringens.

    Abstract translation: 提供了包含SEQ ID NO：1的至少10个连续氨基酸的NetB表位多肽，并且与SEQ ID NO：3中的等同位置相比，在氨基酸130和297之间的至少一个位置具有突变，突变 优选地位于边缘结构域内，所述多肽能够结合与SEQ ID NO：1结合的抗体，并且与SEQ ID NO：1的毒性相比具有降低的毒性。 该多肽可用于使受试者免疫产气荚膜梭菌感染。

    Epsilon toxin epitopes from Clostridium perfringens with reduced toxicity
    5.
    发明授权
    Epsilon toxin epitopes from Clostridium perfringens with reduced toxicity 有权
    来自产气荚膜梭菌的Epsilon毒素表位具有降低的毒性

    公开(公告)号：US09573981B2

    公开(公告)日：2017-02-21

    申请号：US14387809

    申请日：2013-03-28

    Applicant: UNIVERSITY OF EXETER

    Inventor： Richard W. Titball ,  Monika Bokori-Brown ,  Claire Naylor

    IPC: A61K39/08 ,  C07K14/33 ,  C07K16/12 ,  A61K39/00

    CPC classification number: C07K14/33 ,  A61K39/00 ,  A61K39/08 ,  C07K16/1282

    Abstract: There is provided an epsilon toxin epitope polypeptide comprising a sequence of at least 10 contiguous amino acids from SEQ ID NO:3, the sequence comprising a mutation of at least one tyrosine residue compared to the equivalent sequence in SEQ ID NO:3, the polypeptide being capable of binding an antibody which binds to SEQ ID NO:5 and having reduced toxicity compared with the toxicity of SEQ ID NO:5. The polypeptide is useful in a method of vaccinating a subject against developing a disease caused by clostridium perfringens and/or caused by (or associated with the presence of) active epsilon toxin.

    Abstract translation: 提供了包含SEQ ID NO：3的至少10个连续氨基酸的序列的ε-毒素表位多肽，所述序列包含与SEQ ID NO：3中的等同序列相比至少一个酪氨酸残基的突变，所述多肽 能够结合与SEQ ID NO：5结合的抗体，并且与SEQ ID NO：5的毒性相比具有降低的毒性。 该多肽可用于接种受试者以发展由产气荚膜梭菌引起的疾病和/或由活性ε毒素（或与其存在）引起的疾病接种的方法。

Patent Agency Ranking